FGF21 and metabolic dysfunction-associated steatohepatitis: In a previous study, we demonstrated that recombinant fibroblast growth factor 21 (FGF21), which is currently in clinical development for the potential treatment of NASH [32], ameliorates HFD-induced hepatic steatosis by improving HIO [26].